Actuate Therapeutics (ACTU) vs Allarity Therapeutics (ALLR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Allarity Therapeutics (ALLR) has outperformed Actuate Therapeutics (ACTU) over the past year, losing 25.9% versus a loss of 96.4%. Actuate Therapeutics is the larger company by market cap ($13.6 million vs $12.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACTU | ALLR |
|---|---|---|
| Share price | $0.2253 | $0.785 |
| Market cap | $13.60M | $12.56M |
| 1-day change | +5.38% | -9.25% |
| YTD return | -96.32% | -27.31% |
| 1-year return | -96.43% | -25.94% |
| EPS (TTM) | $-0.76 | $-0.79 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $320.00K |
| Net income (latest FY) | $-22.23M | $-11.23M |
| Operating margin | — | -3939.06% |
| Net margin | — | -3509.69% |
| 52-week high | $7.90 | $1.84 |
| 52-week low | $0.174 | $0.769 |
| Distance from 52-week high | -97.15% | -57.34% |
| Analyst consensus | none | none |
| Avg. price target upside | +5084.20% | +1301.27% |
| Average volume | 807.24K | 131.74K |
| Shares outstanding | 60.38M | 16.00M |
| Employees | 12 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALLR has outperformed ACTU by 70.5 percentage points over the past year.
About Actuate Therapeutics
ACTU stock →Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Allarity Therapeutics
ALLR stock →Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
ACTU vs ALLR FAQ
Which is bigger, Actuate Therapeutics or Allarity Therapeutics?
Actuate Therapeutics (ACTU) is larger, with a market capitalization of $13.60M compared with $12.56M for Allarity Therapeutics (ALLR).
Which stock has performed better over the past year, ACTU or ALLR?
ALLR returned -25.94% over the past 12 months, compared with -96.43% for ACTU (price return, excluding dividends). Past performance does not predict future results.
Are Actuate Therapeutics and Allarity Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.